The Urology Place has the honor of participating in an international Phase II study investigating the effectiveness, safety and tolerability of an investigational cancer vaccine, which is designed to slow or stop the spread of prostate cancer. 180 patients will be enrolled in the study, world-wide. Over 100 patients are currently already in the study.

In 2018, an initial study with 20 prostate cancer patients was concluded, and results show that the vaccine, RV001, was safe and well-tolerated. The study also showed a strong and lasting immune response from the use of RV001 against prostate cancer spread.

This study is intended for males above the age of 18 who have undergone the removal and/or radiation treatment of their prostate and have noticed a rising Prostate Specific Antigen (PSA). Individuals who are on current therapy such as androgen deprivation (hormone therapy) or have received imaging showing the spread may not participate in this study.

The study will take place in up to 39 centers in six European countries and up to 3 centers in the United States. This study will be conducted over a 36 month period depending on how the cancer responds to the vaccine.

Patients can decline participation at any time.